NS, Yes, I posted yesterday that it was the one thing in the preliminary Q4 report that stood out to me. I haven’t fully grasped the reason or logic behind the decision not to seek FDA guidance and approval for an FDC in the US. I don’t buy that it’s because it won’t sell because doctors can prescribe GV and a generic statin to substitute an AMRN FDC prescription. If they’re developing it for EU and ROW, it shouldn’t cost much to get FDA approval and release it in US too. It doesn’t make sense to me. It’s like not selling Vascepa in the US because doctors and insurers write and cover GV for the CVD indication. It has to be something else at play that KM isn’t divulging. Who cares about doctors and insurers pushing GV and generic statin. The FDC would increase brand awareness, brand loyalty, and increase prescriber and patient use. IMO